Status:
COMPLETED
A 2-year Study of Patients With Schizophrenia Who Are Treated With Long-acting Injectable Risperidone.
Lead Sponsor:
Janssen, LP
Conditions:
Schizophrenia
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to examine treatment practices of adult schizophrenia patients by their own doctors, and to assess patient outcomes when treated with long-acting risperidone injection ove...
Detailed Description
Controlled clinical trials for treating schizophrenia often involve selected patients with common characteristics. It is recognized that schizophrenia are much more diverse than those in the clinical ...
Eligibility Criteria
Inclusion
- Diagnosis of schizophrenia
- long-term use of antipsychotic medication and taking any oral antipsychotic for 4 weeks before the study
- stable with respect to disease symptoms and other medical conditions
- if female, using birth control.
Exclusion
- At risk to self or others
- use of injectable antipsychotics within the past 6 months, of clozapine, or of investigational drugs within 30 days
- considered to be resistant to treatment
- pregnant or breast-feeding
- not using birth control.
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2004
Estimated Enrollment :
650 Patients enrolled
Trial Details
Trial ID
NCT00261430
End Date
October 1 2004
Last Update
May 17 2011
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.